[18F]AlF-NOTA-FAPI-04 PET/CT 作为胃肠道系统肿瘤成纤维细胞激活蛋白显像的有前景工具:与 18F-FDG 对比的前瞻性研究
本研究前瞻性纳入胃肠道系统恶性肿瘤患者,均在一周内完成 18F-FDG 与 18F-FAPI-04 PET/CT 显像,其中 44 例(73.3%)用于肿瘤分期、16 例(26.7%)用于再分期,评估原发灶及淋巴结、远处转移的诊断效能。结果显示 18F-FAPI-04 PET/CT 在原发灶检出、转移性淋巴结诊断及脑、肝、骨、肺、腹膜转移疑似病灶检出方面均优于 18F-FDG PET/CT,并修正了 31.7% 患者的最终诊断、促使 21.7% 患者临床管理发生改变。
要点
- 18F-FAPI-04 PET/CT 检出原发灶的灵敏度为 97.7%,高于 18F-FDG PET/CT 的 72.7%。
- 按淋巴结分析,18F-FAPI-04 PET/CT 诊断转移性淋巴结的灵敏度 91.89%、特异度 92.00%、准确率 91.96%,均高于 18F-FDG PET/CT 的 79.72%、81.33%、80.80%。
- 18F-FAPI-04 PET/CT 修正了 31.7% 患者的最终诊断,并促使 21.7% 患者临床管理发生改变。
核心结论
- 18F-FAPI-04 PET/CT 在勾勒原发性胃肠道肿瘤及检出疑似转移病灶方面优于 18F-FDG PET/CT,归因于更高的靶本比(TBR)。
- 18F-FAPI-04 PET/CT 可为肿瘤分期提供有价值的指导,从而对患者管理具有潜在影响。
研究设计与样本
- 前瞻性纳入诊断为胃肠道系统恶性肿瘤的患者。
- 所有患者均在一周内完成 18F-FDG 与 18F-FAPI-04 PET/CT 扫描,其中 44 例(73.3%)用于肿瘤分期、16 例(26.7%)用于肿瘤再分期。
- 评估原发肿瘤的诊断效能以及淋巴结和远处转移的存在与数量,肿瘤摄取以最大标准摄取值(SUVmax)量化。
主要发现
- 检出原发肿瘤时,18F-FDG PET/CT 的诊断灵敏度为 72.7%,18F-FAPI-04 PET/CT 为 97.7%。
- 基于逐淋巴结分析,18F-FAPI-04 PET/CT 诊断转移性淋巴结的灵敏度、特异度和准确率分别为 91.89%、92.00% 和 91.96%,明显高于 18F-FDG PET/CT 的 79.72%、81.33% 和 80.80%。
- 18F-FAPI-04 PET/CT 在检出脑(7 比 3)、肝(39 比 20)、骨(79 比 51)、肺(11 比 4)和腹膜癌(48 比 22)疑似转移灶方面超过 18F-FDG PET/CT。
- 基于逐患者分析,18F-FAPI-04 与 18F-FDG PET/CT 的鉴别诊断准确率分别为全部患者 91.7% 与 76.7%、初始分期组 90.9% 与 79.5%、再分期组 93.8% 与 68.7%。
- 18F-FAPI-04 PET/CT 修正了 31.7% 患者的最终诊断(对比 18F-FDG PET/CT),并促使 21.7% 患者的临床管理发生改变。
关键数值与推荐
- 原发肿瘤检出灵敏度:18F-FDG PET/CT 72.7% 对比 18F-FAPI-04 PET/CT 97.7%。
- 转移性淋巴结诊断(逐淋巴结):18F-FAPI-04 PET/CT 灵敏度 91.89%、特异度 92.00%、准确率 91.96%,对比 18F-FDG PET/CT 79.72%、81.33%、80.80%。
- 逐患者鉴别诊断准确率:全部患者 18F-FAPI-04 91.7% 对比 18F-FDG 76.7%;初始分期组 90.9% 对比 79.5%;再分期组 93.8% 对比 68.7%。
- 疑似转移灶检出数:脑 18F-FAPI-04 7 个对比 18F-FDG 3 个;肝 39 对比 20;骨 79 对比 51;肺 11 对比 4;腹膜癌 48 对比 22。
- 18F-FAPI-04 PET/CT 修正最终诊断的患者比例为 31.7%,促使临床管理改变的患者比例为 21.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The radiopharmaceutical [18F]AlF-NOTA-FAPI-04 presents a promising alternative to 68 Ga-FAPI owing to its relatively longer half-life. This study aimed to evaluate the clinical usefulness of [18F]AlF-NOTA-FAPI-04 PET/CT for the diagnosis of primary and metastatic lesions in various types of gastrointestinal system cancers, compared with 18F-FDG PET/CT. METHODS: Patients diagnosed with gastrointestinal system malignancies were prospectively enrolled. All patients underwent both 18F-FDG and 18F-FAPI-04 PET/CT scans within one week, with 44 (73.3%) for cancer staging and 16 (26.7%) for tumor restaging. Diagnostic efficacy of the primary tumor, as well as the presence and number of lymph nodes and distant metastases, were assessed. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). RESULTS: For detection of primary tumor, the diagnostic sensitivity of 18F-FDG PET/CT was 72.7%, while it was 97.7% for 18F-FAPI-04 PET/CT. Based on per-lymph node analysis, the sensitivity, specificity, and accuracy of 18F-FAPI-04 PET/CT in diagnosing metastatic lymph nodes were 91.89%, 92.00%, and 91.96%, respectively. These values were notably higher than those 18F-FDG PET/CT (79.72%, 81.33% and 80.80%, respectively). The 18F-FAPI-04 PET/CT surpassed 18F-FDG PET/CT in detecting suspected metastases in the brain (7 vs. 3), liver (39 vs. 20), bone (79 vs. 51), lung (11 vs. 4), and peritoneal carcinoma (48 vs. 22). Based on per-patient analysis, differential diagnostic accuracies (18F-FAPI-04 vs. 18F-FDG PET/CT) were observed in all patients (91.7% vs. 76.7%), the initial staging group (90.9% vs. 79.5%), and the re-staging group (93.8% vs. 68.7%). Additionally, 18F-FAPI-04 PET/CT revised final diagnosis in 31.7% of patients, contrasting with 18F-FDG PET/CT, and prompted changes in clinical management for 21.7% of the patients. CONCLUSION: 18F-FAPI-04 PET/CT outperforms 18F-FDG PET/CT in delineating the primary gastrointestinal tumors and detecting suspected metastatic lesions due to a higher target-to-background ratio (TBR). Moreover, 18F-FAPI-04 PET/CT could provide valuable guidance for tumor staging, thereby having a potential impact on patient management.
引用
- Yang L, Xu S, Cheng L, et al. [18F] AlF‑NOTA‑FAPI‑04 PET/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with 18F-FDG. Eur J Nucl Med Mol Imaging. 2023. PMID: 37542659. doi:10.1007/s00259-023-06351-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。